Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - AKCEA THERAPEUTICS, INC. | akca-ex312_9.htm |
| EX-31.1 - EX-31.1 - AKCEA THERAPEUTICS, INC. | akca-ex311_8.htm |
| EX-23.1 - EX-23.1 - AKCEA THERAPEUTICS, INC. | akca-ex231_11.htm |
| EX-21.1 - EX-21.1 - AKCEA THERAPEUTICS, INC. | akca-ex211_7.htm |
| EX-10.15 - EX-10.15 - AKCEA THERAPEUTICS, INC. | akca-ex1015_357.htm |
| EX-10.4 - EX-10.4 - AKCEA THERAPEUTICS, INC. | akca-ex104_278.htm |
| EX-4.5 - EX-4.5 - AKCEA THERAPEUTICS, INC. | akca-ex45_490.htm |
| 10-K - 10-K - AKCEA THERAPEUTICS, INC. | akca-10k_20191231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Damien McDevitt, the Interim Chief Executive Officer of Akcea Therapeutics, Inc., (the “Company”), and Michael MacLean, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:
|
|
(1) |
The Company’s Annual Report on Form 10-K for the period ended December 31, 2019, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
(2) |
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: March 2, 2020
|
By: |
/s/ Damien McDevitt |
|
By: |
/s/ Michael MacLean |
|
|
Damien McDevitt |
|
|
Michael MacLean |
|
|
Interim Chief Executive Officer |
|
|
Chief Financial Officer |
A signed original of this written statement required by Section 906 has been provided to Akcea Therapeutics, Inc. and will be retained by Akcea Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.